Beyond Dystonia: The Therapeutic Benefits of Botulinum Toxin Type A in Neurological Disorders
BoNT type A (BoNT-A) is a neurotoxic protein produced by the anaerobic bacterium Clostridium botulinum . In recent years, BoNT-A has demonstrated substantial efficacy in the management of various diseases, particularly neurological disorders, and has served as a versatile therapeutic agent in modern medicine. This review is aimed at comprehensively examining the application of BoNT-A in various non-dystonia disorders—including hyperhidrosis, salivation, chronic migraine, trigeminal neuralgia, postherpetic neuralgia, primary tremor, depression, and Parkinson’s disease—in the field of neurology.
Authors
- Ying Kiat Tan (ORCID: https://orcid.org/0000-0002-0118-5049)
- Yang Li (ORCID: https://orcid.org/0000-0003-4022-7341)
- Haohao Zhu (ORCID: https://orcid.org/0000-0003-2352-4854)
- Weifeng Luo
- Wei Wei (ORCID: https://orcid.org/0009-0006-9318-4313)
Publication Details
- Journal
- Neuropharmacology and Therapy
- Published
- 2025-01-01
- DOI
- https://doi.org/10.15212/npt-2024-0014
- Citations
- 1
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province